Simple urine test could help HIV-Negative women stick to PrEP

NCT ID NCT03935464

Completed Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a new urine test that measures tenofovir levels to see how well HIV-negative women are taking their daily PrEP medication. Researchers provided real-time feedback based on the test results, along with standard counseling, to 100 women. The goal was to see if this approach is acceptable and feasible for improving adherence to PrEP.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: urine-based tenofovir adherence assay (behavioral intervention with feedback)
What this could lead to: If successful, this could provide a simple, real-time urine test to help people on PrEP stay adherent and reduce HIV risk.
What could go wrong: This is a small pilot study (100 participants) focused on feasibility, not effectiveness. The test may not improve adherence in larger, more diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RISK REDUCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Risk Reduction Behavior HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RISK REDUCTION

Contacts and locations

Locations

KEMRI Partners in Health and Research Development (PHRD), Thika

Thika, Near Nairobi, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.